首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >Evaluation of dried blood spots as an alternative matrix for therapeutic drug monitoring of abiraterone and delta(4)-abiraterone in prostate cancer patients
【24h】

Evaluation of dried blood spots as an alternative matrix for therapeutic drug monitoring of abiraterone and delta(4)-abiraterone in prostate cancer patients

机译:将干燥血液作为替代基质的替代基质,用于治疗药物监测AbiraTerone和Delta(4)中的前列腺癌患者

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Therapeutic drug monitoring (TDM) approaches may benefit patients treated with abiraterone acetate (AA) as drug efficacy is imprecise and important pharmacokinetic variability is known. Current methods based on the analysis of plasma present the disadvantage of the fast degradation of the analytes in the liquid sample. Dried blood spots (DBS) consist of a minimally invasive and unexplored sampling strategy to monitor the levels of abiraterone (ABI) and delta(4)-abiraterone (D4A) in patients. This study presents the development and validation of a precise and accurate method to monitor ABI and D4A in DBS samples by UPLC-MS/MS. Bioanalytical method validation was carried out according to current guidelines, evaluating the impact of DBS-specific parameters such as hematocrit and spot volume on accuracy. Based on the analysis of quality control samples prepared at low, medium and high concentrations, the method was precise with CV <= 6.97 % and 10.26 % for ABI and D4A, respectively. The method was also highly accurate, between 93.6-106.8 % for ABI and 96.0-108.5 % for D4A. The DBS method is compatible with the analysis of samples of unknown volume and hematocrit range of the studied population. In addition, ABI and D4A were stable for 7 days in DBS at room temperature, which is feasible for sample transportation in postal service and analysis in the laboratory. Method application to 16 clinical samples revealed good correlation between measured plasma concentrations and estimated plasma concentrations for ABI (r = 0.884, P < 0.05) and D4A (r = 0.920, P < 0.05). Passing-Bablok regression analysis and Bland-Altmann plots indicated correlation between the results obtained from DBS and plasma, with a slight overestimation of the concentrations of ABI in DBS, which could be related to the small study cohort. Therefore, the results of this first work indicate that DBS consist of a promising alternative sampling strategy in TDM studies of AA. (C) 2020 Elsevier B.V. All rights reserved.
机译:治疗性药物监测(TDM)方法可能有利于使用醋酸阿比特龙(AA)治疗的患者,因为药物疗效不精确,且已知重要的药代动力学变化。目前基于等离子体分析的方法存在液体样品中分析物快速降解的缺点。干血点(DBS)由一种微创且未经探索的采样策略组成,用于监测患者体内的阿比特龙(ABI)和δ(4)-阿比特龙(D4A)水平。本研究开发并验证了一种通过UPLC-MS/MS监测DBS样本中ABI和D4A的精确方法。生物分析方法验证是根据当前指南进行的,评估了DBS特定参数(如红细胞压积和斑点体积)对准确性的影响。根据对低、中、高浓度下制备的质控样品的分析,该方法的精密度为ABI和D4A的CV分别小于等于6.97%和10.26%。该方法的准确度也很高,ABI为93.6-106.8%,D4A为96.0-108.5%。DBS方法适用于研究人群未知体积和红细胞压积范围的样本分析。此外,ABI和D4A在室温下在DBS中稳定7天,这对于邮政服务中的样品运输和实验室分析是可行的。方法应用于16例临床样本,发现ABI(r=0.884,P<0.05)和D4A(r=0.920,P<0.05)的测量血浆浓度与估计血浆浓度之间存在良好的相关性。通过Bablok回归分析和Bland Altmann图表明DBS和血浆结果之间存在相关性,DBS中ABI的浓度略微高估,这可能与小型研究队列有关。因此,第一项工作的结果表明,DBS在AA的TDM研究中是一种很有前途的替代抽样策略。(C) 2020爱思唯尔B.V.版权所有。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号